SexyMD review

There is a separately priced microdose on both molecules and each is a genuine saving against the seller's own standard month-to-month rate, which is the structure worth finding for anybody intending to stay small. Two things about the presentation matter. The microdose pages carry a plan-length table in exactly the format the full-dose pages use for real discounts, and every rung in it is the same number — four weeks, eight weeks and twelve weeks all cost the same — so a table that looks like a ladder offers nothing for committing. And every headline figure across the site is the forty-eight-week commitment rate rather than the month-to-month one, marked with an asterisk that never resolves to a footnote. The tirzepatide microdose page also contradicts itself on how often you inject, saying twice a week in the body copy and once a week in the instructions, which is not a detail a reader should have to arbitrate. Compounding is disclosed as a class only, prescriptions may move between unnamed pharmacies without notice, and no individual clinician is named.

Vs median

$7/mo above the $172 median across the 254 of 393 programs we track that publish a plain monthly rate

Market

$59–$1300/mo is the full published spread in our ranking

Structure

Charges less for less

Consult

Billed separately

Dietitian

Not included

Labs

Not required

Pricing

Varies by dose, plan or tier

Price last updated

September 2026

SexyMD dispenses through a 503A and 503B network — no pharmacy named facility. No bloodwork is required before you start. A clinician review is billed separately.

SexyMD sells compounded semaglutide and compounded tirzepatide, each in a full-dose version and a separately priced microdose, and the microdose is genuinely cheaper — $179 against $269 on semaglutide and $259 against $369 on tirzepatide. For a reader intending to stay small that is the structure worth finding. Two things about how it is presented matter. The microdose pages carry a plan-length table in the same format as the full-dose pages, and every rung in it is the same number: four weeks, eight weeks and twelve weeks all cost $179, so the table looks like a discount ladder and offers no discount. And every headline figure across the site is the forty-eight-week commitment rate rather than the month-to-month one, marked with an asterisk that never resolves to a footnote. The tirzepatide microdose page contradicts itself on how often you inject, saying twice a week in the body copy and once a week in the instructions. Compounding is disclosed as a class only, prescriptions may be moved between unnamed pharmacies without notice, and no individual clinician is named.

THE MICRODOSE PRICES FOUR, EIGHT AND TWELVE WEEKS IDENTICALLY — a plan-length table with no plan-length discount, in the same format that carries real rungs on the full-dose pages

• Every headline price on the site is the forty-eight-week commitment rate, against month-to-month rates seventy dollars higher, and the asterisk never resolves to a footnote
• The same footer says both that service is available in all fifty states and that it is available in all states except three
• The tirzepatide microdose page says twice a week in its body copy and once a week in its instructions
• The twenty-four and forty-eight-week tiers print a monthly figure and ship every twelve weeks; the actual charge amount and cadence are not published
• The checkout claims two patient counts on consecutive screens that together exceed twenty-seven thousand in a single day, on a site whose own badge says eight hundred
• Placeholder Lorem ipsum posts are live and listed in the site's own index as the blog
• No pharmacy is named, no individual clinician is named, no milligram is published, and no support hours are given
• Compounded GLP-1s are not FDA-approved, and intentional microdosing is off-label and unproven

SexyMD is one of 393 low-dose GLP-1 programs we track, and 254 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• What microdosing GLP-1 costs
• What the evidence actually shows
• Low dose vs full dose
• The true annual cost of a plan
• What a flat price costs at a low dose